In an adult patient with cardiogenic shock, what are the recommended first‑line pharmacologic agents, dosing regimens, and adjunctive therapies for initial management?

Treatment of Cardiogenic Shock: Drugs and Doses

Immediate Diagnostic Assessment

Confirm cardiogenic shock with ECG and bedside echocardiography immediately to identify the underlying cause, assess ventricular function, and exclude mechanical complications such as ventricular septal rupture or acute mitral regurgitation. 1

• Insert an invasive arterial line for continuous blood pressure monitoring—this is a Class I recommendation 2, 1
• Define shock as systolic BP < 90 mmHg for > 30 min plus signs of hypoperfusion: urine output < 30 mL/h, cold extremities, altered mental status, lactate > 2 mmol/L 2
• Obtain arterial blood gas, lactate, renal function, and electrolytes on admission 1
• Consider early pulmonary artery catheter placement when the shock phenotype is unclear or the patient fails initial therapy 2, 1

First-Line Pharmacologic Strategy

Step 1: Cautious Fluid Challenge (If No Overt Overload)

• Administer 200–250 mL isotonic crystalloid over 10–15 minutes only if there are no signs of overt fluid overload (elevated JVP, pulmonary edema, bibasilar crackles) 1, 3
• This step differentiates true cardiogenic shock from hypovolemia and optimizes preload before starting inotropes 1

Step 2: Initiate Dobutamine (First-Line Inotrope)

Start dobutamine at 2–3 µg·kg⁻¹·min⁻¹ without a loading dose; it is the preferred first-line inotrope for raising cardiac output when low output persists after adequate fluid resuscitation. 1, 3

• Titrate upward in increments every few minutes to a maximum of 15–20 µg·kg⁻¹·min⁻¹ based on clinical response 1, 3
• Target cardiac index > 2.0–2.2 L·min⁻¹·m⁻², urine output > 0.5 mL·kg⁻¹·h⁻¹, lactate clearance, and warming of extremities 1, 3
• Monitor continuously for dose-dependent tachyarrhythmias 1

Step 3: Add Norepinephrine (Preferred Vasopressor)

Add norepinephrine when systolic BP remains < 90 mmHg or mean arterial pressure < 65 mmHg despite adequate dobutamine dosing. 1, 3

• Administer via central line at 0.2–1.0 µg·kg⁻¹·min⁻¹, titrating to maintain MAP ≥ 65 mmHg 1, 3
• Norepinephrine is associated with fewer arrhythmias (≈12% vs 24% with dopamine) and lower mortality 1, 3
• Do not use dopamine as first-line therapy—reserve it only for patients with significant bradycardia or when other agents are contraindicated 1, 3

Hemodynamic Targets

• Systolic BP > 90 mmHg 1
• Mean arterial pressure ≥ 65 mmHg 1, 3
• Cardiac index > 2.0–2.2 L·min⁻¹·m⁻² 2, 1
• Pulmonary capillary wedge pressure < 20 mmHg 2, 1
• Urine output > 0.5 mL·kg⁻¹·h⁻¹ 1, 3
• Progressive lactate clearance 1, 3

Alternative Inotropes for Refractory Cases

Levosimendan

• Consider when dobutamine + norepinephrine fail to achieve hemodynamic stability, especially in patients on chronic β-blockers 1, 3
• Dose: 12 µg·kg⁻¹ bolus over 10 min, then 0.1 µg·kg⁻¹·min⁻¹ infusion 1, 3
• Acts via calcium sensitization and phosphodiesterase-3 inhibition, independent of β-adrenergic receptors 1, 3
• Contraindicated if systolic BP < 85 mmHg unless combined with a vasopressor 3

Milrinone

• Alternative phosphodiesterase-3 inhibitor, useful in patients receiving β-blockers 1, 3
• Dose: 25–75 µg·kg⁻¹ bolus, then 0.375–0.75 µg·kg⁻¹·min⁻¹ infusion 3
• Recent data show no superiority over dobutamine 3
• Longer half-life complicates titration 3

Vasopressin

• May be considered in refractory shock requiring high-dose catecholamines 4
• Starting dose: 0.03 units/minute for post-cardiotomy shock 4
• Titrate up by 0.005 units/minute at 10–15 minute intervals 4
• Limited data for doses above 0.1 units/minute 4

Critical Pitfalls to Avoid

• Do not use epinephrine as an inotrope or vasopressor in cardiogenic shock—it is reserved for cardiac arrest situations only 1, 3
• Avoid combining multiple inotropes simultaneously; if dobutamine-norepinephrine regimen fails, proceed to mechanical circulatory support rather than adding further agents 1, 3
• Do not delay revascularization in acute MI-related shock—emergent coronary angiography within 2 hours is the only therapy proven to reduce mortality 5
• Avoid routine IABP use—the IABP-SHOCK II trial showed no mortality benefit 1, 5
• Use the lowest effective doses for the shortest possible duration to limit myocardial oxygen consumption and arrhythmia risk 1, 3

Escalation to Mechanical Circulatory Support

• When optimal medical therapy (dobutamine + norepinephrine ± levosimendan) does not achieve adequate hemodynamics, early consideration of mechanical circulatory support is recommended 1, 3
• Transfer patients to a tertiary center equipped with 24/7 cardiac catheterization and mechanical support capabilities if such resources are not immediately available 1, 5
• Activate a multidisciplinary shock team (interventional cardiology, cardiac surgery, heart failure specialists, critical care physicians)—this approach is associated with 39% reduction in 30-day mortality 1

Duration and Weaning

• Tolerance to continuous inotropic infusion typically develops after 24–48 hours 1
• Wean dobutamine gradually by decreasing the infusion in 2 µg·kg⁻¹·min⁻¹ steps while optimizing oral vasodilator therapy 1
• Continue vasopressor and inotropic support until stable blood pressure and tissue perfusion are maintained without pharmacologic assistance, then taper slowly to avoid rebound hypotension 1